Your browser doesn't support javascript.
loading
Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Visseaux, Benoit; Assoumou, Lambert; Mahjoub, Nadia; Grude, Maxime; Trabaud, Mary-Anne; Raymond, Stéphanie; Wirden, Marc; Morand-Joubert, Laurence; Roussel, Catherine; Montes, Brigitte; Bocket, Laurence; Fafi-Kremer, Samira; Amiel, Corinne; De Monte, Anne; Stefic, Karl; Pallier, Coralie; Tumiotto, Camille; Maillard, Anne; Vallet, Sophie; Ferre, Virginie; Bouvier-Alias, Magali; Dina, Julia; Signori-Schmuck, Anne; Carles, Marie-Josée; Plantier, Jean-Christophe; Meyer, Laurence; Descamps, Diane; Chaix, Marie-Laure.
Afiliação
  • Visseaux B; IAME, Université de Paris, AP-HP, UMR 1137, INSERM, Virology, Hôpital Bichat, AP-HP, Paris, France.
  • Assoumou L; Centre National de Référence VIH, Paris, France.
  • Mahjoub N; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Grude M; Hopital Saint-Louis, Virology, Paris, France.
  • Trabaud MA; AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Raymond S; Hôpital de la Croix Rousse, Virology, Lyon, France.
  • Wirden M; CHU Purpan, Virology, Toulouse, France.
  • Morand-Joubert L; CHU Pitié-Salpêtrière, Virology, Paris, France.
  • Roussel C; AP-HP, Hôpital Saint-Antoine, Laboratoire de virologie, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (iPLESP), Paris, France.
  • Montes B; CHU Amiens, Virology, Amiens, France.
  • Bocket L; CHU Montpellier, Virology, Montpellier, France.
  • Fafi-Kremer S; CHU Lille, Virology, Lille, France.
  • Amiel C; CHU Strasbourg, Virology, Strasbourg, France.
  • De Monte A; Hopital Tenon, Virology, Paris, France.
  • Stefic K; CHU Nice, Virology, Nice, France.
  • Pallier C; INSERM U1259, Université de Tours, CHU Tours, Virology, Tours, France.
  • Tumiotto C; Hopital Paul Brousse HUPS, Villejuif, France.
  • Maillard A; CHU Bordeaux, Virology, Bordeaux, France.
  • Vallet S; CHU Rennes, Virology, Rennes, France.
  • Ferre V; CHU Brest, Virology, Brest, France.
  • Bouvier-Alias M; CHU Nantes, Virology, Nantes, France.
  • Dina J; CHU Henri Mondor, Virology, Créteil, France.
  • Signori-Schmuck A; CHU Caen, Caen, France.
  • Carles MJ; CHU Grenoble Alpes, Virology, Grenoble, France.
  • Plantier JC; CHU-Nimes, Virology, Nimes, France.
  • Meyer L; Normandie University, UNIROUEN Rouen, EA2656, Rouen University Hospital, Virology, Rouen, France.
  • Descamps D; INSERM SC10 US19, Villejuif, INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, France.
  • Chaix ML; IAME, Université de Paris, AP-HP, UMR 1137, INSERM, Virology, Hôpital Bichat, AP-HP, Paris, France.
J Antimicrob Chemother ; 75(1): 183-193, 2020 01 01.
Article em En | MEDLINE | ID: mdl-31641777
ABSTRACT

OBJECTIVES:

Patients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.

METHODS:

A total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.

RESULTS:

Patients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P=0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.

CONCLUSIONS:

Since 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variação Genética / Infecções por HIV / HIV-1 / Farmacorresistência Viral / Monitoramento Epidemiológico Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variação Genética / Infecções por HIV / HIV-1 / Farmacorresistência Viral / Monitoramento Epidemiológico Idioma: En Ano de publicação: 2020 Tipo de documento: Article